Jones Anna, Rodgers Kay, Jeffrey Debbie, Ali Waqas I, Andreyev Hjn
Research & Innovation Team, Lincolnshire Community Health Services NHS Trust, Lincoln, UK.
Oncology, United Lincolnshire Hospitals NHS Trust, Lincoln, UK.
Frontline Gastroenterol. 2021 Dec 20;14(2):167-170. doi: 10.1136/flgastro-2021-102013. eCollection 2023.
Immune checkpoint inhibition is the standard-of-care for many advanced cancers. Side effects of therapy may prevent optimal treatment of the cancer. Management of side effects is dominated by recommendations derived from oncological, not gastroenterological practice. We report a patient who developed pancreatic insufficiency during checkpoint inhibitor therapy with a programmed cell death receptor 1 inhibitor, nivolumab, which if not diagnosed would have prevented ongoing treatment. This is a problem which affects approximately 1 in 100 patients treated with this agent but is rarely recognised. Gastroenterologists need to be aware of the spectrum of gastrointestinal disorders which occur after immunotherapy to treat cancer.
免疫检查点抑制是许多晚期癌症的标准治疗方法。治疗的副作用可能会妨碍对癌症的最佳治疗。副作用的管理主要依据肿瘤学而非胃肠病学实践得出的建议。我们报告了一名患者，在使用程序性细胞死亡受体1抑制剂纳武单抗进行检查点抑制剂治疗期间出现了胰腺功能不全，如果未被诊断出来，将会妨碍持续治疗。这是一个影响约1%接受该药物治疗患者的问题，但很少被认识到。胃肠病学家需要了解免疫治疗癌症后发生的一系列胃肠道疾病。
